Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activity in patients with heavily pretreated chronic lymphocytic leuk...

Descripción completa

Detalles Bibliográficos
Autores principales: Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745995/
https://www.ncbi.nlm.nih.gov/pubmed/31723767
http://dx.doi.org/10.1097/HS9.0000000000000039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745995/
https://www.ncbi.nlm.nih.gov/pubmed/31723767
http://dx.doi.org/10.1097/HS9.0000000000000039

Ejemplares similares